Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

ADDF-Harrington partnership accelerates the translation of innovative Alzheimer's research into therapies

The Alzheimer's Drug Discovery Foundation and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, Associate Professor in Medicine at the Cardiovascular Research Center and the McCance Center for Brain Health at Massachusetts General Hospital and the Harvard Medical School in Boston.

12 Jan 2023

Study may help explain how excess weight can contribute to diabetes

People who are overweight or obese have a significantly increased risk of developing diabetes, but exactly how that happens is not well understood.

11 Jan 2023

Developing new tools to accelerate spatial genomics and drug discovery

We speak to Dr. George Emanuel from Vizgen about their new MERSCOPE Platform and how it is accelerating the field of drug discovery by combining both single-cell and spatial genomics.

From Vizgen 10 Jan 2023

Using machine learning models to guide the design of long-acting injectable drug formulations

Scientists at the University of Toronto have successfully tested the use of machine learning models to guide the design of long-acting injectable drug formulations.

10 Jan 2023

Ubiquigent appoints Dr Xavier Jacq to Scientific Advisory Board

Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced the appointment of Dr Xavier Jacq to its Scientific Advisory Board (SAB).

10 Jan 2023

New Bruker-Biognosys collaboration aims to deliver advanced proteomics CRO services

Bruker Corporation and Switzerland-based Biognosys AG today announced a strategic partnership, in which Bruker has made a majority-ownership investment in Biognosys. Financial details were not disclosed. J.P.Morgan acted as exclusive financial advisor to Biognosys.

From Bruker BioSpin - NMR, EPR and Imaging 10 Jan 2023

Clinically relevant biomarker strategies in drug development

In this interview, NewsMedical speaks with Dr. Justin Devine and Dr. Nicholas Woudberg about biomarkers, their importance for drug development as well as the potential they have when it comes to machine learning.

From Synexa Life Sciences BV 9 Jan 2023

High affinity antibodies isolated to safely target Claudin 6-positive tumors

Integral Molecular, the industry leader in antibody discovery for membrane proteins, has published the targeting mechanism enabling best-in-class specificity of its Claudin 6 (CLDN6) antibody CTIM-76 being developed for cancer therapy with Context Therapeutics.

6 Jan 2023

Researchers develop a new approach to better understand the biology of polycystic kidney disease

A research team supported by the National Institutes of Health has developed a new approach to better understand the biology of polycystic kidney disease (PKD), an often-life-threatening genetic disorder that affects millions worldwide.

5 Jan 2023

Insilico Medicine launches a 6th generation Intelligent Robotics Drug Discovery Laboratory

Insilico Medicine, a clinical stage, end-to-end artificial intelligence (AI)-driven drug discovery company, held the launch ceremony for Life Star – a 6th generation Intelligent Robotics Drug Discovery Laboratory – in Suzhou BioBAY Industrial Park on Dec. 29.

5 Jan 2023

PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a multi-project drug discovery collaboration with Boehringer Ingelheim, one of the world-leading pharmaceutical companies developing innovative therapies for diseases with unsatisfactory treatments.

From PhoreMost 5 Jan 2023

Orbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugs

...

From Orbit Discovery 5 Jan 2023

Incurable liver disease could be reversed with a single drug

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the liver, could be reversed with a single drug.

4 Jan 2023

Insilico announces nomination of preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy

Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company's drug discovery team has nominated a preclinical candidate targeting KAT6A for ER+/HER2- breast cancer therapy utilizing its end-to-end Pharma.AI platform.

27 Dec 2022

New method uses artificial DNA to target and kill cancer cells

Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely new way.

21 Dec 2022

CN Bio appoints Dr Paul Brooks as Chief Executive Officer

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr Paul Brooks, formerly the Company’s Chief Business Officer, to the position of CEO with immediate effect. Former CEO, Dr David Hughes, will continue to work with the company in a consultative role within the Company’s Scientific Advisory Board.

From CN-Bio 19 Dec 2022

New imaging agent lights the way for surgeons during lung cancer surgery

Surgery, especially surgery to remove cancerous tumors, relies on a range of tools and techniques as well as on the skill of the surgeon.

19 Dec 2022

PhoreMost and ThinkCyte collaborate to advance AI based drug discovery

PhoreMost Ltd. and ThinkCyte K.K today announced a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).

From PhoreMost 16 Dec 2022

New clue may explain why women are at greater risk for Alzheimer's disease

Scientists at Scripps Research and Massachusetts Institute of Technology (MIT) have found a clue to the molecular cause of Alzheimer's-;a clue that may also explain why women are at greater risk for the disease.

15 Dec 2022

People with cocaine- and opioid-use disorders infected with COVID-19 have greater risk of endocarditis

People diagnosed with cocaine- and opioid-use disorders are more susceptible to developing endocarditis, a condition that damages the lining of the heart valves and chambers, according to research from the Case Western Reserve University School of Medicine and National Institute on Drug Abuse, part of the National Institutes of Health.

14 Dec 2022